BioPharma Dive August 5, 2024
Sponsored content By MMIT
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical. Today’s molecular-targeted therapies have very different treatment paradigms, not to mention cost structures.
While it stands to reason that purportedly curative therapies, like those for hemophilia, would require more intensive education campaigns, the need for greater pharma investment in physician education is not limited to precision medicines. Evidence-based physician education is now an essential element of market access planning for any new drug, regardless of whether it is the first therapy in...
Today's Sponsors
Today's Sponsor